Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRCA2 Mutation as a Possible Cause of Poor Response to 177Lu-PSMA Therapy.

Clinical nuclear medicine - 1 Aug 2018

Ahmadzadehfar Hojjat, Gaertner Florian, Lossin Philipp S, Schwarz Bettina, Essler Markus

Abstract excerpt

We present the case of a 66-year-old man with castration-resistant prostate cancer, with an increasing prostate-specific antigen level, and a progressive disease during Lu-PSMA radionuclide therapy. Because the patient had a BRCA2 mutation, poly-ADP ribose polymerase inhibitor therapy was started. The patient showed a dramatic subjective and biological response to this therapy with a progression-free survival of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to BRCA2 Protein
Share to Dipeptides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA2 gene

Share to Mutation

Share to Prostate-Specific Antigen

Share to Prostatic Neoplasms, Castration-Resistant

Share to Treatment Outcome

Source

Identifiers

PMID: 29762244
DOI: 10.1097/RLU.0000000000002141

Genes

BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

BRCA2 Mutation as a Possible Cause of Poor Response to 177Lu-PSMA Therapy.PMID 29762244Read ↗

Image-Guided Fine-Needle Aspiration Cytology for BRCA Mutation Assessment of PSMA-Positive Lymph Node Metastases in a Patient With Metastatic Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

Exceptional Duration of Radium-223 in Prostate Cancer With a BRCA2 Mutation.Semantic proximity Read ↗

BRCA2 mutations should be screened early and routinely as markers of poor prognosis: evidence from 8,988 patients with prostate cancerSemantic proximity Read ↗

Prostate Cancer in a Patient with a Family History of BRCA Mutation: a Case Report and Literature Review.Semantic proximity Read ↗

Genomic instability is associated with response to [¹⁷⁷Lu]Lu-PSMA-I&T radioligand therapy: an exploratory, preliminary liquid biopsy analysisSemantic proximity Read ↗

A novel germline BRCA2 mutation in a Chinese patient with prostate cancer sensitive to platinum chemotherapy: a case report.Semantic proximity Read ↗

Association between DNA damage repair alterations and outcomes to 177Lu-PSMA-617 in advanced prostate cancerSemantic proximity Read ↗

Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.